Login / Signup

TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.

Michela CortesiMichele ZanoniRoberta MaltoniSara RavaioliMaria Maddalena TumedeiFrancesca PiriniSara Bravaccini
Published in: Expert opinion on therapeutic targets (2022)
ADCs targeting Trop2 recently received an accelerated FDA approval for the therapy of metastatic TNBC. The prospects for these novel ADCs in BC subtypes other than TNBC are discussed, taking into account the main pitfalls relative to Trop2 structure and function.
Keyphrases
  • cell surface
  • squamous cell carcinoma
  • small cell lung cancer
  • cancer therapy
  • current status
  • stem cells
  • adverse drug
  • drug induced
  • drug delivery